Core Viewpoint - CalciMedica, Inc. has initiated an underwritten public offering of its common stock to support its clinical-stage biopharmaceutical development focused on CRAC channel inhibition therapies for inflammatory and immunologic diseases [1][2]. Company Overview - CalciMedica is a clinical-stage biopharmaceutical company that develops novel therapies targeting CRAC channels to modulate immune responses and protect against tissue cell injury [6]. - The company’s lead product candidate, Auxora™, has shown positive results in multiple clinical trials, including a Phase 2b trial for patients with acute pancreatitis and systemic inflammatory response syndrome (SIRS) [6]. - CalciMedica is conducting ongoing trials, including a Phase 2 trial for acute kidney injury (AKI) with data expected in 2025 [6]. Offering Details - The public offering will consist entirely of shares sold by the company, with a potential 30-day option for the underwriter to purchase an additional 15% of the shares [2]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective in August 2023 [4].

Company Overview - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses [3] - The company's lead product candidate, Auxora™, has shown positive clinical results in multiple completed efficacy trials [3] - CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, California [3] Clinical Trials and Presentations - A late-breaking abstract for a plenary presentation by Prof. Robert Sutton from the University of Liverpool has been accepted for the ACG 2024 Annual Scientific Meeting, scheduled for October 28-30 in Philadelphia [1] - The presentation will focus on the CARPO clinical trial, which studies acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS) [1][2] - CalciMedica is currently conducting several clinical trials, including a Phase 2b trial (CARPO) for AP with SIRS, a Phase 2 trial (KOURAGE) for acute kidney injury (AKI) with associated acute hypoxic respiratory failure (AHRF), and a Phase 1/2 trial (CRSPA) for acute intestinal pseudo-obstruction (AIPT) [3]

Core Insights - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases [3] Company Overview - CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury [3] - The company aims to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies [3] - CalciMedica's lead product candidate, Auxora™, has shown positive and consistent clinical results in multiple completed efficacy clinical trials [3] Clinical Trials - The company has announced topline data for a Phase 2b trial (CARPO – NCT04681066) in patients with acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS) [3] - A Phase 2 trial (CARDEA – NCT04345614) in patients with COVID pneumonia has been completed [3] - Currently, CalciMedica is conducting a Phase 2 trial (KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxic respiratory failure (AHRF), with data expected in 2025 [3] - The company is also supporting an ongoing Phase 1/2 trial (CRSPA – NCT04195347) in patients with acute inflammatory pulmonary thrombosis (AIPT), with data also expected in 2025 [3] Upcoming Events - Rachel Leheny, Ph.D., CEO of CalciMedica, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedica, Inc. (Exact name of Registrant as specified in its Charter) Delaware 45-2120079 (State or other jurisdiction o ...

Exhibit 99.1 CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., August 12, 2024 – CalciMedica Inc. ("CalciMedica or the Company") (Nasdaq: CALC), a clinic ...

Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRA ...

Forward-Looking Statements Topline data expected in 2025 Development of Auxora in AKI is supported by both clinical and pre-clinical evidence LA JOLLA, Calif., July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the first patient has been dosed ...

LA JOLLA, Calif., July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium releaseactivated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at two upcoming healthcare investment conferences: Live webcasts of both presentations can be accessed in the "Upc ...

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's U.S. indexes serve as the benchmark for about $10.5 trillion in assets as of the close of December 2023. Russell indexes are part of FTSE Russell, a leading global index provider. CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMed ...

Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7% reduction in severe organ failure in all patients versus placebo Up to 100% reduction in hospital stays longer than 21 days Planning End-of-Phase 2 meeting with the FDA in preparation for a pivotal trial Conference call to discuss the C ...